of Screening Compounds
Drug Discovery Services
Pharma News, 2019
Israeli firm announces successful trials of oral insulin drug for treating diabetes
COI Pharmaceuticals Announces Acquisition of Calporta by Merck
SAN DIEGO--(BUSINESS WIRE)--COI Pharmaceuticals, the Community Of Innovation established by Avalon Ventures, today announced the acquisition of Calporta Therapeutics, Inc.
AstraZeneca plans 2020 filing for anifrolumab in lupus
AstraZeneca is planning to file for approval of anifrolumab in systemic lupus erythematosus (SLE) in the second half of next year.
Fingerprint test can distinguish between those who have taken or handled heroin
A state-of-the-art fingerprint detection technology can identify traces of heroin on human skin, even after someone has washed their hands - and it is also smart enough to tell whether an individual h...
World's first robot-assisted brain aneurysm surgery performed in Canada
Microsoft AI helps diagnose cervical cancer faster
In some cases, AI-assisted cancer detection might be more than a convenience -- it could be the key to getting a diagnosis in the first place.
Roche’s risdiplam meets primary endpoint in pivotal SUNFISH trial in people with type 2 or 3 spinal muscular atrophy
Basel, 11 November 2019 – Roche (SIX.
AstraZeneca Reports Pooled Cardiovascular Safety and Efficacy Analyses of Roxadustat in P-III Program for CKD Patients with Anaemia
The P-III program involves assessing of Roxadustat vs PBO and epoetin alfa in 9,000+ NDD and DD & ID patients in multiple studies conducted by AstraZeneca, FibroGen and Astellas together globa...
Vaccine against Ebola: Commission grants first-ever market authorisation
Today, the European Commission adopted the decision granting marketing authorisation to the company Merck Sharp & Dohme B.
FDA Grants Priority Review to Opdivo-Yervoy Combo in Advanced HCC
The FDA has accepted the supplemental biologics license application and granted breakthrough therapy designation to nivolumab (Opdivo) plus ipilimumab (Yervoy) for the treatment of pat...
Roche Discontinues Trial of Duchenne Muscular Dystrophy Drug RG6206
Roche has discontinued a phase 2/3 trial of RG6206 after a futility analysis showed that the drug was “highly unlikely” to demonstrate clinical benefit in patients with Duchenne muscular dystrophy...
Novo Nordisk obtains exclusive worldwide licence to potential NASH candidate UD-014 from UBE Industries
Novo Nordisk A/S and UBE Industries Ltd.
Go to cart
You will be able to Pay Online or Request a Quote
Catalog of Screening Compounds
Focused and Target Libraries
Active Reference Sets
Drug Discovery Services
In silico Drug Design (CADD)
Toxicology and Safety
Chemistry, Manufacturing and Controls
News & Media
Trends in discovery compounds